Short-term implantation effects of a DCPD-based calcium phosphate cement.
Calcium phosphate cements can be handled in paste form and set in a wet medium after precipitation of calcium phosphate crystals in the implantation site. Depending on the products entering into the chemical reaction leading to the precipitation of calcium phosphates, different phases can be obtained with different mechanical properties, setting times and injectability. We tested a cement composed of a powder, containing beta-tricalcium phosphate (beta-TCP) and sodium pyrophosphate mixed with a solution of phosphoric and sulphuric acids. The cement set under a dicalcium phosphate dihydrate (DCPD)-based matrix containing beta-TCP particles. This was injected with a syringe into a defect drilled in rabbit condyles, the control being an identical defect left empty in the opposite condyle. The condyles were analysed histologically 2, 6 and 18 weeks after implantation. After injection into the bone defect the cement set and formed a porous calcium phosphate structure. Two different calcium phosphate phases with different solubility rates could be identified by scanning electron microscopy (SEM) observation. The less-soluble fragments could be degraded by cell phagocytosis in cell compartments of low pH or integrated in the newly formed bone matrix. The degradation rate of the material was relatively high but compatible with the ingrowth of bone trabeculae within the resorbing material. The ossification process was different from the creeping substitution occurring at the ceramic contact. Bone did not form directly at the cement surface following the differentiation of osteoblasts at the material surface. The trabeculae came to the material surface from the edges of the implantation site. Bone formation in the implantation site was significantly higher than in the control region during the first week of implantation. In conclusion, this material set in situ was well tolerated, inducing a mild foreign-body reaction, which did not impair its replacement by newly formed bone within a few weeks.
Frayssinet
P
P
Laboratoire du Tissu Osseux et des Pathologies Ostéoarticulaires, Université Paul Sabatier, Toulouse, France.
Gineste
L
L
Conte
P
P
Fages
J
J
Rouquet
N
N
D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology*; D001843:Bone Cements / Q000494:pharmacology*; D002130:Calcium Phosphates / Q000494:pharmacology*; D011756:Diphosphates / Q000494:pharmacology; D005260:Female; D008335:Mandibular Condyle / Q000166:cytology / Q000187:drug effects* / Q000648:ultrastructure; D008855:Microscopy, Electron, Scanning; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects; D019736:Prostheses and Implants; D019919:Prosthesis Implantation / Q000379:methods; D011817:Rabbits; D013499:Surface Properties; D013997:Time Factors
D001672:Biocompatible Materials; D001843:Bone Cements; D002130:Calcium Phosphates; D011756:Diphosphates; C485828:alpha-tricalcium phosphate; C485817:beta-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; C020243:calcium phosphate; C018392:tricalcium phosphate; C485829:calcium phosphate, dibasic, anhydrous; C003319:sodium pyrophosphate